Apteka na Suraskiej Marek Morusiewiczsp. k.
KRS: NIP: REGON:
Overview
Status
Active
Registry date
2013-03-01
Registered address
Suraska 4/20, 15-422 Białystok, Poland
Financials
Revenue history (in k)
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 19 days late).
- 202510/06/2026
- 202420/06/2025
- 202305/07/2024
- 202215/07/2023
- 202103/08/2022
- 202016/07/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 1.70mMedianUSD 164.14kAverageUSD 2.27m
Net profit
This companyUSD 63.00kMedianUSD 1.03kAverageUSD 108.21k
Operating costs
This companyUSD 1.58mMedianUSD 187.05kAverageUSD 2.07m
Assets
This companyUSD 411.79kMedianUSD 115.76kAverageUSD 1.52m
Industry
Partners
| Partners | Partner role |
|---|---|
Jacek Romanowskiage 54 | General partner |
| General partner | |
Anna Kienigage 71 | General partner |
Manner of representation
General partner independently
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2013-04-24.
61 1050 1953 1000 0090 8096 9711
72 1050 1953 1000 0091 3397 7588
73 1050 1953 1000 0091 3397 7570
Debt
No entries in the National Debtors Register (KRZ).
Public aid
5 public aid cases recorded, with a total value of $33,517.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,821$1,821 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Jul 1, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | STAROSTA POWIATU BIAŁYSTOCKIEGO | |
| Jun 24, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $26,155$26,155 | Polski Fundusz Rozwoju S.A. |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| PoltregS.A. | $1,906,011.66 | poltreg.com | ||
| Przedsiębiorstwo Farmaceutyczne Sulphur Zdrój Eximsp. z o.o. | $1,592,037.83 | sulphur.com.pl | ||
| Labor Przedsiębiorstwo Farmaceutyczno - Chemicznesp. z o.o. | $1,184,204.34 | labor.com.pl | ||
| Natur DayS.A. | $680,635.59 | naturday.pl | ||
| Biotriosp. z o.o. | $453,662.22 | biotrio.pl | ||
| Nature's Voicesp. z o.o. | $181,977.76 | naturesvoice.eu | ||
| Pexon Polandsp. z o.o. | $122,615.96 | pexon.pl | ||
| Bioresearch PharmaS.A. | $21,432.15 | bioresearchpharma.com | ||
| Grupa FinepharmS.A. | – | finepharm.pl | ||
| Dobre Zdrowiesp. z o.o. | – | dobrezdrowie.eu |
FAQ
The company was registered in the Polish National Court Register (KRS) on March 1, 2013.
The headquarters is located at: Suraska 4, 15-422 Białystok.
The legal form of this entity is a limited partnership (sp.k.).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $1,698,708, representing an increase of 6.1% compared to 2024.
Yes, in 2025 the company was profitable, achieving a net profit of $63,001, meaning the company decreased its profit by 28.4%.
The largest operating cost category falls under cost of goods and materials sold. This category amounted to $1,205,944 in 2025, representing 77% of all operating expenses.
Last updated: 2026-06-10